Anne T Berg1, Francine M Testa, Susan R Levy. 1. Epilepsy Center, Children's Memorial Hospital, Northwestern University, Chicago, IL, USA. atberg@childrensmemorial.org
Abstract
OBJECTIVE: Determine the probability of attaining complete remission in children with nonsyndromic epilepsy (NSE) over the course of ≥10 years from initial diagnosis; identify early predictors of complete remission; and assess the risk of relapse after achieving complete remission. METHODS: In a prospective community-based cohort, complete remission was defined as 5 years seizure-free and medication-free. Any subsequent seizure for any reason was a relapse. Univariate and bivariate analyses were conducted with standard methods including the Kaplan-Meier approach. Proportional hazards modeling was used for multivariable analysis. RESULTS: Of 613 cohort members, 347 had NSEs, of whom 294 (85%) were followed ≥10 years (maximum = 17.9). A total of 170 in 294 (58%) achieved complete remission, 10 of whom (6%) relapsed. Seizure outcome at 2 years (remission, pharmacoresistant, unclear) (p < 0.0001) and underlying cause (p < 0.0001) distinguished groups with complete remission ranging from ~20% to ~75%. Older age at onset was independently associated with a poorer chance of complete remission. Relapses occurred up to 7.5 years after attaining complete remission and were marginally associated with underlying cause (p = 0.06). INTERPRETATION: Complete remission occurs in over one-half of young people with NSE and generally persists. Meaningful but imperfect predication is possible based on underlying cause and early seizure control. The finding of age effects may play a role in meaningful identification of phenotypes, which could become fruitful targets for genetic and imaging investigations in these otherwise poorly differentiated epilepsies.
OBJECTIVE: Determine the probability of attaining complete remission in children with nonsyndromic epilepsy (NSE) over the course of ≥10 years from initial diagnosis; identify early predictors of complete remission; and assess the risk of relapse after achieving complete remission. METHODS: In a prospective community-based cohort, complete remission was defined as 5 years seizure-free and medication-free. Any subsequent seizure for any reason was a relapse. Univariate and bivariate analyses were conducted with standard methods including the Kaplan-Meier approach. Proportional hazards modeling was used for multivariable analysis. RESULTS: Of 613 cohort members, 347 had NSEs, of whom 294 (85%) were followed ≥10 years (maximum = 17.9). A total of 170 in 294 (58%) achieved complete remission, 10 of whom (6%) relapsed. Seizure outcome at 2 years (remission, pharmacoresistant, unclear) (p < 0.0001) and underlying cause (p < 0.0001) distinguished groups with complete remission ranging from ~20% to ~75%. Older age at onset was independently associated with a poorer chance of complete remission. Relapses occurred up to 7.5 years after attaining complete remission and were marginally associated with underlying cause (p = 0.06). INTERPRETATION: Complete remission occurs in over one-half of young people with NSE and generally persists. Meaningful but imperfect predication is possible based on underlying cause and early seizure control. The finding of age effects may play a role in meaningful identification of phenotypes, which could become fruitful targets for genetic and imaging investigations in these otherwise poorly differentiated epilepsies.
Authors: Anne T Berg; Barbara G Vickrey; Francine M Testa; Susan R Levy; Shlomo Shinnar; Frances DiMario; Susan Smith Journal: Ann Neurol Date: 2006-07 Impact factor: 10.422
Authors: Miranda Geelhoed; Anne Olde Boerrigter; Peter Camfield; Ada T Geerts; Willem Arts; Bruce Smith; Carol Camfield Journal: Epilepsia Date: 2005-09 Impact factor: 5.864
Authors: William D Gaillard; Catherine Chiron; J Helen Cross; A Simon Harvey; Ruben Kuzniecky; Lucie Hertz-Pannier; L Gilbert Vezina Journal: Epilepsia Date: 2009-04-06 Impact factor: 5.864
Authors: Anne T Berg; John T Langfitt; Francine M Testa; Susan R Levy; Francis DiMario; Michael Westerveld; Joseph Kulas Journal: Epilepsia Date: 2007-12-06 Impact factor: 5.864
Authors: Anne T Berg; Gary W Mathern; Richard A Bronen; Robert K Fulbright; Francis DiMario; Francine M Testa; Susan R Levy Journal: Brain Date: 2009-07-28 Impact factor: 13.501
Authors: Danella M Hafeman; Tina R Goldstein; Michael Strober; John Merranko; Mary Kay Gill; Fangzi Liao; Rasim S Diler; Neal D Ryan; Benjamin I Goldstein; David A Axelson; Martin B Keller; Jeffrey I Hunt; Heather Hower; Lauren M Weinstock; Shirley Yen; Boris Birmaher Journal: Bipolar Disord Date: 2021-01-19 Impact factor: 5.345
Authors: Seo Young Lee; Soo Eun Chung; Dong Wook Kim; So Hee Eun; Hoon Chul Kang; Yong Won Cho; Sang Do Yi; Heung Dong Kim; Ki Young Jung; Hae Kwan Cheong Journal: J Clin Neurol Date: 2016-06-03 Impact factor: 3.077
Authors: A M Wahle; A Brühschwein; K Matiasek; K Putschbach; E Wagner; R S Mueller; A Fischer Journal: J Vet Intern Med Date: 2013-11-16 Impact factor: 3.333